Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 2Sarcoma 2Gastrointestinal 2Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Ovarian Neoplasms 25Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 8Endometrial Neoplasms 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 4Stomach Neoplasms 4Recurrence 4Peritoneal Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Hepatocellular 2Tumor Virus Infections 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma 1Lung Neoplasms 1Locally Advanced Cervical Carcinoma 1Locally Advanced Cervical Cancer 1Gallbladder Neoplasms 1Dysgerminoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Cervical Adenocarcinoma 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Gemcitabine 7Cyclophosphamide 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Albumin-Bound Paclitaxel × Gynecologic × Clear all
NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
194 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University

Phase 2 Recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT00466986 2011-10-12

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Southeastern Gynecologic Oncology

Phase 2 Completed
40 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡